Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 1.00 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060742 | 0.95 | ALDH1A1 (0.90) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 | |
| 6-Nitroquipazine SCHEMBL4266383 | 0.91 | ALDH1A1 (1.00) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 | |
| 6-Nitroquipazine SCHEMBL4266389 | 0.91 | ALDH1A1 (1.00) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 | |
| 6-Nitroquipazine SCHEMBL4266387 | 0.91 | ALDH1A1 (1.00) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 | |
| SCHEMBL5873582 | 0.86 | ALDH1A1 (0.76) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 | |
| SCHEMBL3559642 | 0.84 | ALDH1A1 (0.72) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 | |
| SCHEMBL6421125 | 0.84 | ALDH1A1 (0.72) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 | |
| SCHEMBL6365197 | 0.83 | ALDH1A1 (0.70) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 | |
| SCHEMBL13666128 | 0.82 | ALDH1A1 (0.69) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 | |
| SCHEMBL31373520 | 0.82 | ALDH1A1 (0.69) | ALDH1A1HTR3EHTR3BCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105636438-A | Pharmaceutical composition comprising an AMPK activator and a serotonin active agent and uses thereof | CHEN JIANHONG | 2016-06-01 | — | — | CN | claimed |
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| EP-2111394-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | Solvay Pharmaceuticals B.V. (NL) | 2009-10-28 | — | — | EP | claimed |
| US-20080214559-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2008-09-04 | — | — | US | claimed |
| WO-2008084057-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-07-17 | — | — | WO | claimed |
| EP-1435930-A2 | ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2004-07-14 | — | — | EP | claimed |
| WO-2003082286-A1 | QUINOLINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHEMON INC. (KR) | 2003-10-09 | — | — | WO | claimed |
| WO-2003032969-A2 | ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2003-04-24 | — | — | WO | claimed |
| US-20020173511-A1 | Serotonergic compositions and methods for treatment of mild cognitive impairment | WURTMAN RICHARD J (US) | 2002-11-21 | — | — | US | claimed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | claimed |
| US-5372813-A | Measurement of serotonin uptake sites in a sample using a radio labeled substituted 6-nitroquipazine as a radioligand | THE REGENTS, UNIVERSITY OF CALIFORNIA (US) | 1994-12-13 | — | — | US | claimed |
| US-5120641-A | Incubating with sample, determining radioactivity | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 1992-06-09 | — | — | US | claimed |
| EP-0435192-A2 | Method for measurement of serotonin uptake sites and radioligand therefor | DAIICHI PURE CHEMICALS CO. LTD. (JP) | 1991-07-03 | — | — | EP | claimed |
| JP-3199969-A | — | — | None | — | — | JP | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
| US-4877788-A | ANXIOLYTIC, ANTIAGGRESSIVE OR ANTIPSYCHOTIC AGENT | ADIR ET CIE (FR) | 1989-10-31 | — | — | US | disclosed |
| WO-1989003692-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214559-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | CNR1, OPRL1, CNR2 | ALDH1A1 435/4885HTR3E 45/4885HTR3B 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.